BRAIN Biotech AG Appoints Johan Jansen-Storbacka to Lead Enzyme Products Business

BRAIN Biotech AG has appointed Johan Jansen-Storbacka as Executive Vice President of the BRAINBiocatalysts' enzyme products business, effective September 1, 2025. Jansen-Storbacka succeeds Rod Sears-Black, who retired earlier this year, and brings more than 20 years of experience in biotechnology with extensive expertise in enzyme applications spanning industrial processes, animal nutrition, and home care.

In his new role, Jansen-Storbacka will oversee approximately 140 employees and manage fermentation facilities in the UK along with production sites in continental Europe and the United States. His appointment represents a strategic move by BRAIN Biotech to strengthen its enzyme and fermentation business while ensuring closer integration of research and production activities across the organization. The company operates through its website at https://www.brain-biotech-group.com.

Adriaan Moelker, CEO of BRAIN Biotech, emphasized the significance of this appointment, stating that Jansen-Storbacka's broad industry background will be valuable in serving diverse end markets. His international experience and leadership skills position him as an ideal fit for leading the enzyme products business segment. Jansen-Storbacka holds both an M.Sc. in Engineering and Management and an MBA, providing him with the technical and business acumen necessary for this executive role.

The BRAIN Biotech Group, which generated revenue of €54.6 million in the 2023/24 fiscal year with approximately 300 employees, specializes in researching, developing, and producing specialty enzymes for the food and life sciences industries. The company's operations are divided into two main segments: BRAINBiocatalysts, which focuses on development, production, and distribution of specialty enzymes, microorganisms, and ingredients, and BRAINBioIncubator, which handles research-intensive development projects and pharmaceuticals.

This leadership appointment comes at a time when the biotechnology sector is experiencing significant growth, particularly in enzyme applications that enable more sustainable industrial processes and products. The company's fermentation capabilities, detailed at https://www.biocatalysts.com/, play a crucial role in developing microbial production strains and scalable bioprocesses for economic production of specialty enzymes and other proteins. Jansen-Storbacka's extensive experience in international markets and diverse enzyme applications positions BRAIN Biotech to better serve global customers while driving innovation in biological solutions for industry.